AstraZeneca Historical Financial Ratios

AZN Stock

USD 73.58 0.87 1.17%

AstraZeneca PLC is presently reporting on over 101 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0386, PTB Ratio of 4.74 or Days Sales Outstanding of 63.3 will help investors to properly organize and evaluate AstraZeneca PLC ADR financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About AstraZeneca Financial Ratios Analysis

AstraZeneca PLC ADRFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate AstraZeneca PLC investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on AstraZeneca financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across AstraZeneca PLC history.

AstraZeneca PLC Financial Ratios Chart

At this time, AstraZeneca PLC's Free Cash Flow Per Share is very stable compared to the past year. As of the 16th of February 2025, ROIC is likely to grow to 0.17, while Price To Sales Ratio is likely to drop 3.58.

Price To Sales Ratio Dividend Yield Ptb Ratio Days Sales Outstanding

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing AstraZeneca PLC ADR stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on AstraZeneca PLC sales, a figure that is much harder to manipulate than other AstraZeneca PLC ADR multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is AstraZeneca PLC ADR dividend as a percentage of AstraZeneca PLC stock price. AstraZeneca PLC ADR dividend yield is a measure of AstraZeneca PLC stock productivity, which can be interpreted as interest rate earned on an AstraZeneca PLC investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Most ratios from AstraZeneca PLC's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into AstraZeneca PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2022	2023	2024	2025 (projected)
Dividend Yield	0.0208	0.0212	0.0227	0.0386
Price To Sales Ratio	4.73	4.6	3.76	3.58

Dividend Yield Price To Sales Ratio

AstraZeneca PLC fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Invested Capital	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio
Price To Sales Ratio		-0.34	1.0	-0.83	-0.59	-0.34	0.74	-0.45	-0.79	0.54	1.0	1.0	-0.35	0.24	-0.17	-0.32	0.11	-0.14	0.3	-0.11	-0.58	1.0	-0.17	-0.08	0.24	1.0
Dividend Yield	-0.34		-0.32	0.42	-0.08	0.56	-0.24	0.07	0.26	0.18	-0.32	-0.35	0.02	0.5	0.57	0.54	-0.54	-0.34	-0.28	0.31	0.68	-0.33	0.59	-0.26	-0.02	-0.33
Ptb Ratio	1.0	-0.32		-0.82	-0.59	-0.32	0.74	-0.44	-0.79	0.56	1.0	1.0	-0.35	0.26	-0.14	-0.3	0.09	-0.15	0.3	-0.1	-0.56	1.0	-0.15	-0.09	0.23	1.0
Days Sales Outstanding	-0.83	0.42	-0.82		0.66	0.6	-0.58	0.64	0.63	-0.35	-0.82	-0.83	0.55	-0.02	0.51	0.46	-0.45	-0.03	-0.23	0.16	0.74	-0.83	0.47	0.04	-0.32	-0.83
Book Value Per Share	-0.59	-0.08	-0.59	0.66		0.33	-0.18	0.84	0.23	-0.29	-0.59	-0.59	0.77	-0.13	0.2	0.36	-0.19	0.12	0.25	-0.16	0.12	-0.6	0.29	0.36	-0.41	-0.62
Free Cash Flow Yield	-0.34	0.56	-0.32	0.6	0.33		-0.27	0.57	0.28	-0.27	-0.32	-0.35	0.7	0.46	0.75	0.62	-0.64	-0.24	-0.12	-0.25	0.73	-0.34	0.71	-0.11	-0.74	-0.36
Invested Capital	0.74	-0.24	0.74	-0.58	-0.18	-0.27		-0.01	-1.0	0.61	0.74	0.74	0.0	0.4	0.01	-0.02	-0.09	-0.41	0.72	-0.21	-0.63	0.73	0.18	-0.14	0.33	0.73
Operating Cash Flow Per Share	-0.45	0.07	-0.44	0.64	0.84	0.57	-0.01		0.06	-0.07	-0.44	-0.45	0.93	0.19	0.51	0.58	-0.49	-0.2	0.4	-0.09	0.22	-0.46	0.58	-0.07	-0.49	-0.48
Average Payables	-0.79	0.26	-0.79	0.63	0.23	0.28	-1.0	0.06		-0.62	-0.79	-0.79	0.04	-0.4	0.01	0.05	0.07	0.4	-0.7	0.2	0.64	-0.79	-0.15	0.14	-0.32	-0.78
Capex To Depreciation	0.54	0.18	0.56	-0.35	-0.29	-0.27	0.61	-0.07	-0.62		0.56	0.54	-0.28	0.46	0.1	0.15	-0.18	-0.38	0.34	0.57	-0.29	0.54	0.23	-0.32	0.57	0.55
Pb Ratio	1.0	-0.32	1.0	-0.82	-0.59	-0.32	0.74	-0.44	-0.79	0.56		1.0	-0.35	0.26	-0.14	-0.3	0.09	-0.15	0.3	-0.1	-0.56	1.0	-0.15	-0.09	0.23	1.0
Ev To Sales	1.0	-0.35	1.0	-0.83	-0.59	-0.35	0.74	-0.45	-0.79	0.54	1.0		-0.36	0.24	-0.17	-0.32	0.12	-0.13	0.3	-0.11	-0.59	1.0	-0.18	-0.08	0.24	1.0
Free Cash Flow Per Share	-0.35	0.02	-0.35	0.55	0.77	0.7	0.0	0.93	0.04	-0.28	-0.35	-0.36		0.22	0.54	0.53	-0.49	-0.13	0.32	-0.4	0.24	-0.37	0.56	-0.02	-0.72	-0.4
Roic	0.24	0.5	0.26	-0.02	-0.13	0.46	0.4	0.19	-0.4	0.46	0.26	0.24	0.22		0.46	0.8	-0.45	-0.64	0.31	-0.1	0.16	0.24	0.82	-0.5	-0.05	0.24
Inventory Turnover	-0.17	0.57	-0.14	0.51	0.2	0.75	0.01	0.51	0.01	0.1	-0.14	-0.17	0.54	0.46		0.47	-0.98	-0.29	0.03	0.0	0.54	-0.17	0.64	-0.29	-0.34	-0.17
Net Income Per Share	-0.32	0.54	-0.3	0.46	0.36	0.62	-0.02	0.58	0.05	0.15	-0.3	-0.32	0.53	0.8	0.47		-0.44	-0.55	0.25	-0.02	0.4	-0.32	0.89	-0.42	-0.25	-0.33
Days Of Inventory On Hand	0.11	-0.54	0.09	-0.45	-0.19	-0.64	-0.09	-0.49	0.07	-0.18	0.09	0.12	-0.49	-0.45	-0.98	-0.44		0.31	-0.13	-0.05	-0.43	0.12	-0.6	0.35	0.23	0.12
Payables Turnover	-0.14	-0.34	-0.15	-0.03	0.12	-0.24	-0.41	-0.2	0.4	-0.38	-0.15	-0.13	-0.13	-0.64	-0.29	-0.55	0.31		-0.57	-0.08	-0.05	-0.14	-0.59	0.51	-0.18	-0.14
Average Inventory	0.3	-0.28	0.3	-0.23	0.25	-0.12	0.72	0.4	-0.7	0.34	0.3	0.3	0.32	0.31	0.03	0.25	-0.13	-0.57		-0.17	-0.51	0.3	0.28	-0.15	0.15	0.29
Capex To Revenue	-0.11	0.31	-0.1	0.16	-0.16	-0.25	-0.21	-0.09	0.2	0.57	-0.1	-0.11	-0.4	-0.1	0.0	-0.02	-0.05	-0.08	-0.17		0.17	-0.11	-0.07	-0.22	0.54	-0.08
Cash Per Share	-0.58	0.68	-0.56	0.74	0.12	0.73	-0.63	0.22	0.64	-0.29	-0.56	-0.59	0.24	0.16	0.54	0.4	-0.43	-0.05	-0.51	0.17		-0.58	0.48	-0.04	-0.35	-0.57
Pocfratio	1.0	-0.33	1.0	-0.83	-0.6	-0.34	0.73	-0.46	-0.79	0.54	1.0	1.0	-0.37	0.24	-0.17	-0.32	0.12	-0.14	0.3	-0.11	-0.58		-0.17	-0.08	0.25	1.0
Interest Coverage	-0.17	0.59	-0.15	0.47	0.29	0.71	0.18	0.58	-0.15	0.23	-0.15	-0.18	0.56	0.82	0.64	0.89	-0.6	-0.59	0.28	-0.07	0.48	-0.17		-0.36	-0.22	-0.18
Payout Ratio	-0.08	-0.26	-0.09	0.04	0.36	-0.11	-0.14	-0.07	0.14	-0.32	-0.09	-0.08	-0.02	-0.5	-0.29	-0.42	0.35	0.51	-0.15	-0.22	-0.04	-0.08	-0.36		-0.16	-0.09
Capex To Operating Cash Flow	0.24	-0.02	0.23	-0.32	-0.41	-0.74	0.33	-0.49	-0.32	0.57	0.23	0.24	-0.72	-0.05	-0.34	-0.25	0.23	-0.18	0.15	0.54	-0.35	0.25	-0.22	-0.16		0.29
Pfcf Ratio	1.0	-0.33	1.0	-0.83	-0.62	-0.36	0.73	-0.48	-0.78	0.55	1.0	1.0	-0.4	0.24	-0.17	-0.33	0.12	-0.14	0.29	-0.08	-0.57	1.0	-0.18	-0.09	0.29

Click cells to compare fundamentals

AstraZeneca PLC Account Relationship Matchups

AstraZeneca PLC fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	4.93	4.45	4.73	4.6	3.76	3.58
Dividend Yield	0.0272	0.0232	0.0208	0.0212	0.0227	0.0386
Ptb Ratio	8.4	4.24	5.67	5.39	4.99	4.74
Days Sales Outstanding	52.19	58.83	59.35	66.98	60.28	63.3
Book Value Per Share	11.92	27.71	23.94	25.06	26.3	27.61
Free Cash Flow Yield	0.0167	0.0226	0.0345	0.0311	0.0357	0.0277
Operating Cash Flow Per Share	3.66	4.21	6.34	6.62	7.63	8.01
Stock Based Compensation To Revenue	0.0104	0.0164	0.014	0.0126	0.0114	0.00808
Capex To Depreciation	0.83	0.34	0.47	0.77	0.69	1.3
Pb Ratio	8.4	4.24	5.67	5.39	4.99	4.74
Ev To Sales	5.91	5.4	5.1	5.25	4.22	4.01
Free Cash Flow Per Share	0.39	1.67	2.65	4.68	4.2	4.92
Roic	0.0849	(0.00535)	0.0645	0.0932	0.1	0.17
Inventory Turnover	1.32	1.38	2.64	1.48	1.93	2.52
Net Income Per Share	2.44	0.079	2.12	3.81	4.53	4.75
Days Of Inventory On Hand	277.18	263.63	138.42	246.24	189.1	142.46
Payables Turnover	2.77	2.25	4.4	4.86	0.45	0.43
Capex To Revenue	0.0979	0.0588	0.058	0.0825	0.0848	0.0636
Cash Per Share	6.09	4.51	4.14	3.75	3.64	3.14
Pocfratio	27.34	27.93	21.4	20.39	17.16	16.3
Interest Coverage	3.95	0.81	2.79	5.16	5.74	10.3
Payout Ratio	1.12	34.43	1.33	0.75	0.66	0.63
Capex To Operating Cash Flow	0.52	0.83	0.54	0.37	0.26	0.68
Pfcf Ratio	59.84	44.25	29.0	32.12	27.98	26.58
Days Payables Outstanding	161.87	82.88	75.12	148.32	803.34	843.51
Income Quality	1.23	(22.5)	3.92	1.5	1.36	1.43
Ev To Operating Cash Flow	29.96	32.03	23.75	22.59	19.24	18.27
Pe Ratio	41.06	1.5K	63.83	35.42	28.93	27.48
Return On Tangible Assets	0.0799	0.0462	0.0942	0.002606	0.088	0.14
Ev To Free Cash Flow	65.56	50.75	32.19	35.59	31.36	29.79
Earnings Yield	0.0102	0.0244	6.73E-4	0.0157	0.0282	0.0346
Net Debt To E B I T D A	1.55	4.78	2.54	1.64	1.44	0.73

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving together with AstraZeneca Stock

0.75

LLY

Eli Lilly

Pair Corr

Moving against AstraZeneca Stock

0.68	MRK	Merck Company	Pair Corr
0.55	FDMT	4D Molecular Therapeutics	Pair Corr
0.45	APVO	Aptevo Therapeutics	Pair Corr
0.38	SHG	Shinhan Financial	Pair Corr
0.37	KB	KB Financial Group	Pair Corr

The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.

The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:

How To Invest In AstraZeneca

Details

Is AstraZeneca Stock a good investment?

Details

What is AstraZeneca PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.562

Dividend Share

3.1

Earnings Share

2.25

Revenue Per Share

2.8955

Quarterly Revenue Growth

0.238

The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

AstraZeneca Historical Financial Ratios

About AstraZeneca Financial Ratios Analysis

AstraZeneca PLC Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Ptb Ratio

AstraZeneca PLC fundamentals Correlations

AstraZeneca PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AstraZeneca PLC fundamentals Accounts

Pair Trading with AstraZeneca PLC

Moving together with AstraZeneca Stock

Moving against AstraZeneca Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ptb Ratio	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Price To Sales Ratio
Ev To Sales	+ 1.0	Price To Sales Ratio
Pocfratio	+ 1.0	Price To Sales Ratio
Pfcf Ratio	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio

Average Payables	- 1.0	Invested Capital
Days Of Inventory On Hand	- 0.98	Inventory Turnover
Pfcf Ratio	- 0.83	Days Sales Outstanding
Pocfratio	- 0.83	Days Sales Outstanding
Ev To Sales	- 0.83	Days Sales Outstanding
Days Sales Outstanding	- 0.83	Price To Sales Ratio